Credicorp Ltd. has announced it will enter a quiet period starting October 26, 2026, until the release of its third quarter earnings on November 9, 2026. During this time, the company will not disclose financial information or comment on results to ensure fair dissemination. Credicorp is a leading financial services holding company in Peru with operations across several Latin American countries and the U.S. This quiet period is a standard practice to maintain transparency and fairness before earnings announcements.
Credicorp Ltd.'s upcoming quiet period is noted here with Pluang's snapshot of the Financials sector as context. For readers following Financials, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 142 priced US Financials stocks, 42 rose and 99 fell. Notable movers include XP Inc. Class A Common Stock at USD 30.25 (+3.47%), TeraWulf Inc at USD 12.08 (+3.42%) with a Pluang order activity of 79% Buy, and Allstate Corp at USD 247.78 (+3.41%) with a typical hold time on Pluang of 74 days.
RTX Corporation is set to release its Q3 2026 earnings report on October 20, with Wall Street expecting earnings of $1.78 per share and revenue around $24.1 billion. The company has a strong record of beating earnings estimates for four consecutive q...
The Canadian Investment Regulatory Organization (CIRO) has temporarily halted trading of all shares of Bighorn Metals Corp. (symbol HRNY) as of 1:10 PM ET on October 19, 2026. The halt is pending further information from the company and aims to maint...
The HCA Healthcare Foundation awarded $25,000 to Waypoint (formerly Virginia Home for Boys and Girls) to expand its network of adults trained to support youth mental wellness across Virginia. This funding supports Waypoint's Therapeutic Resources tea...
Angle Advisors has appointed Chris Gessner as a Managing Director, bringing over 20 years of experience in corporate finance, including lending, private equity, and M&A advisory. Gessner's background spans various transaction types and industries suc...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
